UY28126A1 - Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular - Google Patents

Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular

Info

Publication number
UY28126A1
UY28126A1 UY28126A UY28126A UY28126A1 UY 28126 A1 UY28126 A1 UY 28126A1 UY 28126 A UY28126 A UY 28126A UY 28126 A UY28126 A UY 28126A UY 28126 A1 UY28126 A1 UY 28126A1
Authority
UY
Uruguay
Prior art keywords
eye
treatment
dry eyes
drought
rimexolone
Prior art date
Application number
UY28126A
Other languages
English (en)
Inventor
Ernesto J Castillo
John M Yanni
Daniel A Gamache
Steven T Miller
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY28126A1 publication Critical patent/UY28126A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones oftálmicas tópicas y métodos para el tratamiento de la sequedad ocular. Las composiciones y métodos del invento se basan en el descubrimiento de que las propiedades selectivas para la superficie ocular de la rimexolona glucocorticoide hacen que este agente antiinflamatorio sea especialmente apropiado para el tratamiento de la sequedad ocular. Como resultado de la limitada capacidad de la rimexolona de penetrar la córnea, una alta porción de la droga se mantiene en la superficie del ojo, que es el lugar primario de las afecciones inflamatorias asociadas con la sequedad ocular. Esto permite que se utilice una concentración muy baja de la droga, lo que a su vez reduce la posibilidad de un aumento de la presión intraocular y la formación de cataratas.
UY28126A 2002-12-24 2003-12-15 Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular UY28126A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43625502P 2002-12-24 2002-12-24

Publications (1)

Publication Number Publication Date
UY28126A1 true UY28126A1 (es) 2004-06-30

Family

ID=32682365

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28126A UY28126A1 (es) 2002-12-24 2003-12-15 Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular

Country Status (23)

Country Link
US (3) US20040132704A1 (es)
EP (1) EP1575597B1 (es)
JP (1) JP2006513213A (es)
KR (2) KR20090018222A (es)
CN (1) CN100388919C (es)
AR (1) AR042790A1 (es)
AT (1) ATE419856T1 (es)
AU (1) AU2003299696B2 (es)
BR (1) BR0317774A (es)
CA (1) CA2507375C (es)
CY (1) CY1108862T1 (es)
DE (1) DE60325770D1 (es)
DK (1) DK1575597T3 (es)
ES (1) ES2316867T3 (es)
MX (1) MXPA05006985A (es)
PL (1) PL378877A1 (es)
PT (1) PT1575597E (es)
RU (1) RU2330668C2 (es)
SI (1) SI1575597T1 (es)
TW (1) TWI335819B (es)
UY (1) UY28126A1 (es)
WO (1) WO2004058273A1 (es)
ZA (1) ZA200503975B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7779039B2 (en) 2004-04-02 2010-08-17 Salesforce.Com, Inc. Custom entities and fields in a multi-tenant database system
CA2580659C (en) * 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
EP1934812A4 (en) 2005-09-09 2012-01-04 Salesforce Com Inc SYSTEMS AND METHODS FOR EXPORTING, PUBLISHING, BROWSENING AND INSTALLING CUSTOM-CONTROLLED APPLICATIONS IN A DATABASE ENVIRONMENT WITH MULTIPLE DEGRADORS
HUE025173T2 (hu) 2005-12-13 2016-01-28 Incyte Corp Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
US8138156B2 (en) * 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US8629099B2 (en) * 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2437762B1 (en) * 2009-06-05 2017-08-09 Allergan, Inc. Artificial tears and therapeutic uses
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SG10202111768XA (en) 2012-11-15 2021-11-29 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
PE20200298A1 (es) 2013-03-06 2020-02-06 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak
CN114010611B (zh) 2013-08-07 2023-11-28 因赛特控股公司 Jak1抑制剂的持续释放剂型
RU2559580C1 (ru) * 2014-03-18 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Препарат для лечения синдрома "сухого глаза"
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN106581035A (zh) * 2016-12-06 2017-04-26 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合物
CN106420797A (zh) * 2016-12-06 2017-02-22 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合及其制备方法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
RS63312B1 (sr) 2018-01-30 2022-07-29 Incyte Corp Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
KR102269835B1 (ko) 2019-10-08 2021-06-29 한국전력공사 펜형 케이블 식별장치 및 케이블 식별 시스템
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20240166971A1 (en) * 2022-10-26 2024-05-23 Bausch + Lomb Ireland Limited Contact lens treating solution

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
JPS63203620A (ja) * 1985-10-30 1988-08-23 アルコン　ラボラトリ−ズ　インコ−ポレイテツド 眼科用の抗炎症性組成物
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
ES2139005T3 (es) * 1992-04-21 2000-02-01 Schepens Eye Res Inst Terapia ocular con androgeno en el sindrome de sjogren.
JP3337218B2 (ja) * 1992-05-06 2002-10-21 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるホウ酸塩−ポリオール複合体の使用
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
JPH06153607A (ja) * 1992-11-30 1994-06-03 Kinsaku Kida 農耕用作業車と農耕作業部との連結装置
CA2134376C (en) * 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
RU2126669C1 (ru) * 1997-04-25 1999-02-27 Новокузнецкий государственный институт усовершенствования врачей Способ лечения синдрома сухого глаза
PL337458A1 (en) * 1997-06-04 2000-08-14 Akzo Nobel Nv Application of anti-inflammatory steroids in treating chronic intestinal inflammatory diseases
ES2207549T3 (es) * 1999-09-24 2004-06-01 Alcon Inc. Formulaciones en suspension topicas que contienen ciprofloxacino y desametasona.

Also Published As

Publication number Publication date
RU2005123388A (ru) 2006-01-20
CA2507375C (en) 2009-11-24
KR100889170B1 (ko) 2009-03-16
KR20090018222A (ko) 2009-02-19
WO2004058273A1 (en) 2004-07-15
AU2003299696B2 (en) 2009-08-13
KR20050086937A (ko) 2005-08-30
EP1575597A1 (en) 2005-09-21
ATE419856T1 (de) 2009-01-15
US20080096852A1 (en) 2008-04-24
CN100388919C (zh) 2008-05-21
US20040132704A1 (en) 2004-07-08
DK1575597T3 (da) 2009-03-16
CN1732008A (zh) 2006-02-08
AR042790A1 (es) 2005-07-06
DE60325770D1 (de) 2009-02-26
HK1076248A1 (en) 2006-01-13
US20060058277A1 (en) 2006-03-16
AU2003299696A1 (en) 2004-07-22
RU2330668C2 (ru) 2008-08-10
SI1575597T1 (sl) 2009-04-30
CY1108862T1 (el) 2014-07-02
TW200418492A (en) 2004-10-01
CA2507375A1 (en) 2004-07-15
JP2006513213A (ja) 2006-04-20
EP1575597B1 (en) 2009-01-07
BR0317774A (pt) 2005-11-22
PL378877A1 (pl) 2006-05-29
MXPA05006985A (es) 2005-08-16
ES2316867T3 (es) 2009-04-16
ZA200503975B (en) 2006-12-27
TWI335819B (en) 2011-01-11
PT1575597E (pt) 2009-02-02

Similar Documents

Publication Publication Date Title
UY28126A1 (es) Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
UY28709A1 (es) Derivados de prostaglandinas
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
AR043356A1 (es) Dispositvo de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica y uso de inhibidores de la anhidrasa carbonica para su preparacion
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
AR045943A1 (es) Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion
BR112022015579A2 (pt) Composições para tratamento de doenças oculares
ZA202300309B (en) Glucocorticoid-sparing agent
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR051472A1 (es) Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares
CA3167959A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
UY29627A1 (es) Derivados de prostaglandina
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
AR069940A1 (es) Soluciones de irrigacion intraocular y metodos para tratar el edema de cornea

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150519